患者管理方法:遗传性甲状腺髓样癌
遗传性甲状腺髓样癌(hMTC)约占成人病例的25%,由RET原癌基因种系致病性变异引起,导致MEN2A和MEN2B综合征。MEN2具有显著的基因型-表型相关性,可预测疾病谱和发病年龄。遗传检测和系统性治疗的进步使hMTC从晚期发现转变为对无症状RET致病变异携带者的早期检测,管理策略也从激进手术转向基于基因型、生化标志物和影像的个体化方案。
要点
- 约25%的成人甲状腺髓样癌为遗传性,由RET种系致病性变异引起。
- MEN2的基因型-表型相关性可预测hMTC疾病谱和发病年龄。
- 预防性早期甲状腺切除术仍是防止hMTC转移的基石,时机需根据特定致病变异和临床情况个体化。
核心结论
- 遗传性甲状腺髓样癌的管理已从激进的统一手术转向基于基因型、生化标志物和影像的个体化策略,多学科协作对优化患者及家族结局至关重要。
研究设计与样本
- 本文为「患者管理方法」综述,探讨hMTC的诊断评估、手术决策、系统性治疗选择和随访。
主要发现
- 约25%的成人甲状腺髓样癌为遗传性,由RET原癌基因种系致病性变异引起,导致MEN2A和MEN2B综合征。
- MEN2具有显著的基因型-表型相关性,可预测hMTC及其他临床表现的疾病谱和发病年龄。
- 遗传检测和系统性治疗的进步以及對MEN2自然病程的更好理解,使hMTC的临床表现从晚期疾病转变为对无症状RET致病变异携带者的早期检测。
关键数值与推荐
- 预防性早期甲状腺切除术仍是防止转移性hMTC的基石,手术时机根据特定致病变异和临床情况调整。
- 近期靶向系统性治疗的进展为复发和/或转移性疾病患者提供了有前景的选择。
临床怎么用
- hMTC的管理应采用基于基因型、生化标志物和影像发现的个体化策略,并强调多学科协作。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medullary thyroid carcinoma is a rare neuroendocrine tumor originating from calcitonin-secreting parafollicular C cells of the thyroid gland. Approximately 25% of cases in adults are hereditary medullary thyroid carcinoma (hMTC), arising from activating, germline pathogenic variants in the REarranged during Transfection (RET) proto-oncogene and causing the syndromes multiple endocrine neoplasia (MEN) types 2A and 2B. A paradigmatic feature of MEN2 is its robust genotype-phenotype correlations, which predict the disease spectrum and age of onset of hMTC and other clinical manifestations. Advances in genetic testing and systemic therapies and an improved understanding of the natural course of MEN2 have transformed the clinical presentation of hMTC from advanced-stage disease to early detection in asymptomatic RET pathogenic variant carriers. The management of hMTC has similarly evolved from aggressive, one-size-fits-all surgical approaches to personalized strategies informed by genotype, biochemical markers, and imaging findings. Risk-reducing early thyroidectomy remains the cornerstone of metastatic hMTC prevention, with the timing of surgery tailored to the specific pathogenic variant and clinical context. Additionally, recent advances in targeted systemic therapies offer promising options for patients with recurrent and/or metastatic disease. This "Approach to the Patient" article explores the diagnostic evaluation, surgical decision-making, systemic treatment options, and follow-up of patients with hMTC, emphasizing the critical role of multidisciplinary care in optimizing outcomes for patients and their families.
引用
- Shariq OA, Waguespack SG, Hamidi S, et al. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 40105880. doi:10.1210/clinem/dgaf089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。